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Abstract
AIM: To compare venous thromboembolism (VTE) in 
hospitalized ulcerative colitis (UC) patients who respond 
to medical management to patients requiring colectomy. 
METHODS: Population-based surveillance from 1997 
to 2009 was used to identify all adults admitted to 
hospital for a flare of UC and those patients who 
underwent colectomy. All medical charts were reviewed 
to confirm the diagnosis and extract clinically relevant 
information. UC patients were stratified by: (1) re-
sponsive to inpatient medical therapy (n  = 382); (2) 
medically refractory requiring emergent colectomy (n  
= 309); and (3) elective colectomy (n  = 329). The 
primary outcome was the development of VTE during 
hospitalization or within 6 mo of discharge. Heparin 
prophylaxis to prevent VTE was assessed. Logistic 
regression analysis determined the effect of disease 
course (i.e. , responsive to medical therapy, medically 
refractory, and elective colectomy) on VTE after 
adjusting for confounders including age, sex, smoking, 
disease activity, comorbidities, extent of disease, and 
IBD medications (i.e. , corticosteroids, mesalamine, 
azathioprine, and infliximab). Point estimates were 
presented as odds ratios (OR) with 95%CI.
RESULTS: The prevalence of VTE among patients 
with UC who responded to medical therapy was 
1.3% and only 16% of these patients received heparin 
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prophylaxis. In contrast, VTE was higher among pati-
ents who underwent an emergent (8.7%) and elec-
tive (4.9%) colectomy, despite greater than 90% of 
patients receiving postoperative heparin prophylaxis. 
The most common site of VTE was intra-abdominal 
(45.8%) followed by lower extremity (19.6%). VTE 
was diagnosed after discharge from hospital in 16.7% 
of cases. Elective (adjusted OR = 3.69; 95%CI: 
1.30-10.44) and emergent colectomy (adjusted OR = 
5.28; 95%CI: 1.93-14.45) were significant risk factors 
for VTE as compared to medically responsive UC 
patients. Furthermore, the odds of a VTE significantly 
increased across time (adjusted OR = 1.10; 95%CI: 
1.01-1.20). Age, sex, comorbidities, disease extent, 
disease activity, smoking, corticosteroids, mesalamine, 
azathioprine, and infliximab were not independently 
associated with the development of VTE. 
CONCLUSION: VTE was associated with colectomy, 
particularly, among UC patients who failed medical 
management. VTE prophylaxis may not be sufficient to 
prevent VTE in patients undergoing colectomy. 
Key words: Inflammatory bowel diseases; Ulcerative 
colitis; Deep vein thrombosis; Pulmonary embolism; 
Surgery
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The occurrence of venous thromboembolism 
(VTE) in our population-based cohort was about 5%, 
which highlights the importance of this complication 
among hospitalized ulcerative colitis (UC) patients. 
However, the risk of VTE was low (about 1%) among 
flaring ulcerative colitis patients who responded to 
medical management. In contrast, UC patients who 
underwent an elective (5%) or emergent colectomy 
(8.7%) had higher occurrence of VTE. After adjusting 
for covariates the leading risk factor for VTE was the 
need for colectomy. VTE occurred in colectomy patients 
despite > 90% postoperative VTE prophylaxis. Thus, 
heparin prophylaxis may not be sufficient to prevent 
VTE in patients undergoing colectomy. 
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INTRODUCTION
In the western countries the prevalence of ulcerative 
colitis (UC) has been reported as high as 500 cases 
per 100000 persons[1]. Approximately, 16% of UC 
patients will require colectomy within the first 10 
years of diagnosis; though, colectomy rates have 
been decreasing overtime[2,3]. Colectomy for UC 
has been associated with postoperative morbidity 
and mortality[4-6]. An important contributor to post-
operative complications is the occurrence of venous 
thromboembolism (VTE)[7,8], VTE carries risk of 
significant morbidity and mortality, particularly due to 
pulmonary embolism[9-11]. 
The inflammatory bowel diseases (IBD) have 
been established as an independent risk factor 
for developing VTE as well as recurrent VTE[12,13]. 
In recent years, several population-based studies 
showed that IBD patients are at increased risk of 
developing VTE[7,14]. Bernstein et al[7] demonstrated 
that IBD patients have a 3-4 fold increased risk of 
developing a VTE requiring hospitalization. Similar 
rates have been described in both ambulatory and 
hospitalized IBD patients[12,15], while specific studies 
focusing on hospitalized IBD patients showed an 
increased risk of 1.5-2 fold compared to hospitalized 
non-IBD patients[16]. In a meta-analysis the risk of 
VTE among IBD patients was 2-fold higher than 
individuals without IBD[17]. 
Studies have also highlighted some of the po-
tential risk factors behind the development of VTE 
in IBD. One study demonstrated that IBD patients 
experiencing an acute flare that required steroid use 
were associated with an over 8-fold increased risk of 
VTE when compared to non-IBD patients[15]. The risk 
of VTE in IBD was driven by disease severity with 
the risk steadily increasing across IBD patients in 
remission, in a flare managed as an outpatient, and 
a flare managed in-hospital[18]. Among hospitalized 
IBD patients risk factors for VTE included UC, 
advanced age, IBD-related surgery, malnutrition, 
and medical co-morbidities[16,19]. Further, the 
prevalence of VTE among asymptomatic flaring IBD 
patients was low, which suggests that in-hospital 
factors drive the development of VTE[20]. Surgery 
has been recognized as an important risk factor for 
VTE among IBD patients[21,22]. However, studies are 
needed to explore the impact of VTE in UC patients 
who respond to in-hospital medical management 
as compared to those who are refractory to medical 
management and require colectomy. 
Guidelines recommend prophylaxis for VTE using 
anti-coagulants (e.g., subcutaneous heparin) in 
IBD patients who have been hospitalized for a flare 
of disease and following surgery[23,24]. While the 
use of VTE prophylactic doses of heparin in UC is 
recognized as safe[25,26], utilization of VTE prophylaxis 
for hospitalized UC patients in clinical practice may 
be suboptimal[27,28]. In a tertiary care referral center, 
nearly half of UC patients admitted to medical service 
were not provided VTE prophylaxis as compared 
to over 90% who were prescribed in a surgical 
service[27]. However, population-based studies that 
include VTE prescribing practices in community and 
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academic hospitals have not been explored. 
We designed a large population-based study to 
determine the rate of VTE among UC patients who 
underwent an emergent or elective colectomy as 
compared to those who responded to in-hospital 
medical management. Furthermore, we explored 
heparin utilization in clinical practice and the efficacy 
of VTE prophylaxis in this population. 
MATERIALS AND METHODS
Data source
The Data Integration, Measurement and Reporting 
(DIMR) hospital discharge abstract administrative 
database captures all hospitalizations in the Calgary 
Health Zone of Alberta Health Services, Canada. The 
Calgary Health Zone is a population-based health 
authority under a public, single payer system and 
provides all levels of medical and surgical care to the 
residents of the city of Calgary and over 20 nearby 
smaller cities, towns, villages, and hamlets. The 
estimated population of the Calgary Health Zone in 
2009 was 1326115. The DIMR database contains 
42 diagnostic and 25 procedural coding fields. The 
International Classification of Disease, Ninth Revision, 
Clinical Modification (ICD-9-CM) was used up to 2001, 
while ICD-10-CA and the Canadian Classification of 
Health Intervention (CCI) coding have been used 
after 2001[29]. 
Study population
The DIMR administrative discharge database was 
used to identify all adults (≥ 18 years of age) 
who were admitted to hospital with a diagnosis of 
UC (ICD-9-CM 556.X or ICD-10-CA K51.X) and 
underwent colectomy (ICD-9-CM: 45.7 and 45.8 or 
CCI: 1.NM.87, 1.NM.89, 1.NM.91, 1.NQ.89, 1. NQ. 
90) between January 1st, 1997 and December 31, 
2009[4]. Medical chart review confirmed all cases of 
UC and colectomy[29]. UC patients who underwent 
a colectomy were further stratified by emergent 
versus elective operation. An operation was defined 
as “elective” if the decision to operate on the UC 
patient was made prior to admission to hospital. In 
contrast, the decision for an “emergent” colectomy 
was determined during the hospital admission (e.g., 
acute complication or refractory to in-hospital medical 
management)[4]. For a control group, we searched 
the administrative databases for all patients admitted 
to hospital from 1997 to 2009 with UC (ICD-9-CM 
556.X or ICD-10-CA K51.X) coded in the primary 
diagnostic position and a random subset with UC 
coded in the second or third diagnostic position. 
Chart review confirmed that these patients were 
admitted for a flare of UC, but were discharged after 
responding to medical management. These patients 
never underwent colectomy during the course of the 
study period (1997 to 2009)[29].
Outcomes
The primary outcome was the development of VTE. 
Occurrence of VTE was defined according to anatomic 
location: (1) deep vein thrombosis in a limb; (2) 
deep vein thrombosis outside a limb including splenic, 
hepatic, mesenteric, renal, cephalic, subclavian, or 
portal vein thrombosis; and (3) pulmonary embolism, 
diagnosed in isolation or with a co-existing site. The 
diagnosis of VTE was evaluated in two settings: 
(1) diagnosis occurring during hospitalization; and 
(2) readmission to hospital for VTE within 6 mo 
of discharge. Readmission to hospital for VTE was 
included in the study population to capture VTE that 
developed early after admission or during in-hospital 
admission, but only recognized after discharge. 
Among UC patients who underwent an emergent 
colectomy, VTE were classified as preoperative or 
postoperative. 
Variables
The primary variable of interest was the disease 
course, which was evaluated in 3 settings: (1) UC 
patients admitted to hospital for a flare of disease 
and discharged from hospital without colectomy after 
responding to medical mangement; (2) UC patients 
admitted to hospital for flare of UC requiring emergent 
colectomy; and (3) UC patients admitted to hospital 
for elective colectomy. The primary colectomy was 
recorded as the index date and no other UC-related 
bowel surgery was performed prior to the index date. 
In addition, data extracted from hospital records 
included: age at admission to hospital, stratified by 
the tercile of the entire cohort; sex; smoking status 
at hosptial admission (current, ex-smoker, or never 
smoker); disease duration (time from diagnosis of 
UC to admission to hospital); disease activity (> 5 
stool/d and the presence of blood in stool versus ≤ 5 
stool/d or absence of blood); extent of disease (left-
sided colitis, pancolitis, or unknown); and a non-VTE 
in-hospital complication. 
All comorbidities observed in our patients were 
recorded in the following groups as previously de-
scribed[29]: coronary artery disease; congestive 
heart failure; other cardiovascular conditions (e.g., 
arrhythmia); cancer; diabetes; gastrointestinal 
(e.g., pancreatitis); haematological (e.g., anemia); 
hypertension; liver disease (e.g., primary sclerosing 
cholangitis); neurological conditions (e.g., stroke); 
pulmonary disease (e.g., asthma); renal disease (e.g., 
dialysis); rheumatological (e.g., rheumatoid arthritis); 
and thyroid or adrenal disease (e.g., hypothyroidism). 
Comorbidities were classified as having 0 or ≥ 1 and 
have been validated in this population[29].
The chart reviewer determined the use (at time 
of admission or past history) of the following me-
dications: mesalamine or sulfasalazine; azathioprine 
or 6-mercaptopurine; prednisone; and infliximab. 
VTE prophylaxis was evaluated for each UC patient in 
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Ethical considerations
The study was approved by the Conjoint Health 
Research Ethics Board of the University of Calgary.
RESULTS
Between January 1st 1997 and December 31st 2009, 
638 individuals with UC who underwent a colectomy 
(309 emergent and 329 elective) were identified. A 
further 382 UC patients were admitted emergently 
with a flare, but were discharged after responding to 
in-hospital medical management. The characteristics 
of patients with UC are presented in Table 1. The 
overall VTE rate was 4.7%, and 18.8% of these 
individuals experienced a pulmonary embolism. 
The most common site of VTE was intra-abdominal 
(45.8%) followed by lower extremity (19.6%). Table 
2 describes the location of VTE. 
VTE occurred in 1.3% of medically responsive, 
8.7% of emergent colectomy, and 4.9% of elective 
colectomy UC patients (Table 1). Among the em-
ergent colectomy group 88.9% were diagnosed 
with a VTE postoperatively. Among the 48 UC pa-
tients who were diagnosed with VTE, 16.7% were 
diagnosed after discharge from hospital. No patients 
died as a complication of the VTE. Postoperative 
VTE prophylaxis with anticoagulants was prescribed 
in over 90% of patients. However, VTE prophylaxis 
was prescribed preoperatively or prior to discharge 
in less than 20% of patients with UC who underwent 
emergent colectomy or were emergently admitted 
to hospital (i.e., medically responsive), respectively 
(Table 1). 
Among all UC patients (n = 1020), UC patients 
requiring elective colectomy (adjusted OR = 3.69; 
95%CI: 1.30-10.44) and emergent colectomy 
(adjusted OR = 5.28; 95%CI: 1.93-14.45) were 
significantly more likely to be diagnosed with a VTE 
as compared to medically responsive UC patients 
(Table 3). Furthermore, the odds of a VTE significantly 
increased across time (adjusted OR = 1.10; 95%CI: 
1.01-1.20). Patients who underwent emergent 
colectomy (i.e., elective colectomy excluded) were 
significantly more likely to develop a VTE (adjusted 
OR = 4.62; 95%CI: 1.66-12.88) as compared to UC 
patients who were medically responsive. Furthermore, 
an in-hospital complication was associated with an 
increased odds of VTE (adjusted OR = 2.68; 95%CI: 
1.42-5.05) (Table 3). 
DISCUSSION
This study identified a population-based cohort 
of over 1000 hospitalised UC patients. All charts 
were identified to confirm the diagnosis of VTE 
both in-hospital and following discharge. The study 
population was stratified according to the indication 
for admission (i.e., medically responsive UC flare, 
the following settings: (1) in-hospital VTE prophylaxis 
among medically responsive UC flare patients; (2) 
pre- and postoperative VTE prophylaxis among UC 
patients who underwent emergent colectomy; and (3) 
postoperative VTE prophylaxis among UC patients 
who underwent elective colectomy. The primary 
medical VTE prophylaxis used was subcutaneous 
heparin; however, those using low molecular 
weight heparin were included and classified as VTE 
prophylaxis. 
Statistical analysis
We described the occurrence of VTE stratified by 
disease course (i.e., medically responsive to in-
hospital management, emergent colectomy, and 
elective colectomy). For each outcome and study 
variable, descriptive statistics were performed using 
the Fisher Exact test for proportions; continuous 
variables were expressed as medians with in-
terquartile ranges and compared using the Kruskal-
Wallis test. Multivariate logistic regression analysis 
was performed to examine the association between 
disease course (i.e., medically responsive, emergent 
colectomy, and elective colectomy) and VTE after 
adjusting for other clinical variables. Disease course 
and age were a priori forced into the regression 
model. The following variables were subsequently 
evaluated for independent effects on VTE deve-
lopment using the stepwise selection approach 
with 0.1 as the entry and exit P value: sex; year of 
admission; smoking status; comorbidities; disease 
duration; extent of disease; disease activity; in-
hospital complication at anytime during admission 
(i.e., pre- or postoperatively for surgical groups), but 
excluding VTE; and IBD-related medications (i.e., 
mesalamine/sulfasalazine, prednisone, azathioprine/
6-mercaptopurine, and infliximab) prescribed prior 
to admission. These variables were considered 
significant if the two-sided P value was < 0.05. We 
used a stepwise selection approach to adjust our 
model for significant variables, while optimizing the 
efficiency of the model by avoiding overfitting of 
covariates.
In a subanalysis, we compared medically res-
ponsive UC patients to UC patients who underwent an 
emergent colectomy (i.e., elective colectomy patients 
were excluded). We repeated the multivariate logistic 
regression analysis described above, but included a 
variable in the model for the use of VTE prophylaxis 
prior to discharge (i.e.,medically responsive) and 
prior to colectomy. Second, we compared UC patients 
undergoing an elective colectomy to UC patients who 
underwent an emergent colectomy. Similarly, we 
included a variable in the logistic regression model 
that represented VTE prophylaxis for UC patients 
undergoing colectomy. 
All statistical analyses were conducted using SAS 
version 9.3 (SAS Institute Inc., Cary, United States). 
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Characteristics Total cohort 
(n  = 1020)
Elective colectomy 
(n  = 329)
Emergency colectomy 
(n  = 309)
Medically responsive 
(n  = 382)
P  value
Thrombosis < 0.001
   No 95.3 (972)    95.1 (313)   91.3 (282)   98.7 (377)
   Yes 4.7 (48)    4.9 (16)   8.7 (27) 1.3 (5)
Age at Admission (tercile) 0.002
   18-32 33.8 (345) 28.6 (94) 31.7 (98)   40.1 (153)
   33-47 32.6 (333)   33.1 (109) 31.1 (96)   33.5 (128)
   48+ 33.5 (342)   38.3 (126)   37.2 (115)   26.4 (101)
Gender 0.022
   Male 57.0 (581)   61.4 (202)   58.9 (182)   51.6 (197)
   Female 43.0 (439)   38.6 (127)   41.1 (127)   48.4 (185)
Smoking 0.011
   Current 9.8 (94)   7.9 (25)   7.7 (23) 13.3 (46)
   Ex-smokers 33.0 (317) 30.5 (96)   39.0 (117)   30.1 (104)
   Never 57.2 (549)   61.6 (194)   53.3 (160)   56.5 (195)
   Missing (n) n = 60 n = 14 n = 9 n = 37
Comorbidity
   0 comorbidities 46.3 (472)   48.3 (159)   40.5 (125)   49.2 (188) 0.047
   ≥ 1 comorbidities 53.7 (548)   51.7 (170)   59.6 (184)   50.8 (194)
Primary sclerosing cholangitis 0.572
   No 97.6 (996)   97.0 (319)   97.7 (302)   98.2 (375)
   Yes 2.4 (24)   3.0 (10) 2.3 (7) 1.8 (7)
Ankylosing spondylitis or 
sacroiliitis
0.222
   No   99.0 (1010)   99.7 (328)   98.4 (304)   99.0 (378)
   Yes 1.0 (10) 0.3 (1) 1.6 (5) 1.0 (4)
Episcleritis, uveitis and iritis 0.603
   No   98.9 (1009)   98.5 (324)   99.4 (307)   99.0 (378)
   Yes 1.1 (11) 1.5 (5) 0.6 (2) 1.0 (4)
Disease duration, years < 0.001
Median (IQR)     3 (0-9) 6 (2-14) 2 (0-7)       1 (0-6)
   Missing (n) n = 35 n = 18 n = 9 n = 8
Cancer/dysplasia -
   No -   83.0 (273) - -
   Yes 17.0 (56)
Extent of disease < 0.001
   Left-sided 29.4 (265) 23.5 (73) 20.9 (63)   44.5 (129)
   Pancolitis 70.6 (637)   76.5 (237)   79.1 (239)   55.5 (161)
   Missing (n) n = 118 n = 19 n = 7 n = 92
Blood in Stool and Stool 
Frequency > 5/d1
< 0.001
   No 27.0 (217) 46.4 (91) 18.9 (54) 22.3 (72)
   Yes 73.0 (588)   53.6 (105)   81.1 (232)   77.7 (251)
   Missing (n) n = 215 n = 133 n = 23 n = 59
5-ASA2 < 0.001
   No 33.1 (336) 28.0 (91) 26.9 (83)   42.4 (162)
   Yes 66.9 (680)   72.0 (234)   73.1 (226)   57.6 (220)
   Missing (n) n = 4 n = 4
Prednisone2 < 0.001
   No 31.3 (318) 16.6 (54) 22.0 (68)   51.3 (196)
   Yes 68.7 (698)   83.4 (271)   78.0 (241)   48.7 (186)
   Missing (n) n = 4  n = 4
Azathioprine/6-
mercaptopurine2
< 0.001
   No 80.7 (820)   69.2 (225)   80.3 (248)   90.8 (347)
   Yes 19.3 (196)   30.8 (100) 19.7 (61)   9.2 (35)
   Missing (n) n = 4 n = 4
Infliximab2 0.006
   No 96.1 (976)   94.8 (308)   94.5 (292)   98.4 (376)
   Yes 3.9 (40)   5.2 (17)   5.5 (17) 1.6 (6)
   Missing (n) n = 4 n = 4
Complication in hospital3 < 0.001
   0 or Clavien Ⅰ 80.2 (818)   79.9 (263)   64.1 (198)   93.5 (357)
   Clavien Ⅱ/Ⅲ/Ⅳ 19.8 (202) 20.1 (66)   35.9 (111)   6.5 (25)
Postoperative heparin 0.641
   No 6.9 (44)   6.4 (21)   7.4 (23) -
   Yes 93.1 (593)   93.6 (307)   92.6 (286)
   Missing (n) n = 1 n = 1
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Table 1  Characteristics of patients hospitalized for a ulcerative colitis flare, or undergoing a colectomy  n  (%)
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emergent colectomy, or elective colectomy) in order 
to explore the effect of surgery on the risk of VTE. 
We demonstrated that colectomy was significantly 
associated with the development of VTE. VTE 
occurred in about 1% of the medically responsive UC 
patients, whereas UC patients who failed to respond 
to medical management and underwent a colectomy 
had an over 5-fold increased odds of VTE. Similarly, 
UC patients undergoing elective colectomy had an 
over 3-fold increased odds of VTE when compared to 
medically responsive UC inpatients. In contrast, the 
risk of VTE was not associated with disease location, 
or drug utilization including the use of corticosteroids, 
immunomodulators, and biologics. 
VTE occurred in 4.7% of UC patients. These 
occurred in a number of locations including ex-
tremity, intra-abdominal (i.e., portal and hepatic 
vein thrombosis), and pulmonary embolism. VTE 
were confirmed using multiple different testing 
modalities including chest X-ray, D-Dimer, Doppler 
ultrasound of the extremities, V/Q scan, CT PE 
protocol, and angiography. While most VTE were 
identified following the manifestation of clinical 
symptoms, most of the intra-abdominal clots were 
detected incidentally in asymptomatic patients 
on CT scans performed to assess postoperative 
symptoms or complications. While incidental cases 
were primarily identified in postoperative patients 
following colectomy (11 cases among elective 
and 10 cases among emergent colectomy), one 
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1Missing data is defined as missing on either the stool frequency, the presence of blood in stool, or both. 2Defined as medication used prior to or at the 
time of admission to hospital. No refers to no record of drug use in the medical chart. 3Complication was classified as Clavien ≥ Ⅱ. 4Emergent colectomy - 
heparin prophylaxis in hospital prior to colectomy. Medically Responsive - heparin prophylaxis in hospital prior to discharge.
Table 2  Location of venous thromboembolism  n  (%)
Location of VTE Total (n  = 48) Elective colectomy (n  = 16) Emergency colectomy (n  = 27) Medically responsive (n  = 5)
Upper extremity   8 (17.4) 1 (6.3)   6 (22.2) 1 (20.0)
Lower extremity   9 (19.6)   3 (18.8)   6 (22.2) 0
Intra-abdominal 22 (45.8) 11 (68.8) 10 (37.0) 1 (20.0)
Pulmonary embolism   9 (18.8) 1 (6.3)   5 (18.5) 3 (60.0)
VTE: Venous thromboembolism.
Heparin prophylaxis prior to 
surgery/discharge4
0.310
   No 82.9 (572) - 81.2 (251) 84.3 (321)
   Yes 17.1 (118) 18.8 (58) 15.7 (60)
   Missing (n) n = 1 n = 1
Table 3  Independent predictors of venous thromboembolism for all ulcerative colitis patients; those admitted emergently to hospital 
and were medically responsive or underwent emergent colectomy; and those who underwent an emergent or elective colectomy
Full cohort 
VTE (n  = 1020)
Adjusted OR (95%CI)
Emergent and medically responsive cohort 
VTE (n  = 690)1
Adjusted OR (95%CI)
Emergent and elective cohort 
VTE (n  = 637)1
Adjusted OR (95%CI)
Age, yr
   18-32 1.00 1.00 1.00
   33-47 1.56 (0.68-3.56) 2.44 (0.81-7.34) 1.35 (0.56-3.27)
   ≥ 48 1.63 (0.74-3.59) 2.29 (0.79-6.66) 1.65 (0.72-3.75)
Disease course
   Medical responsive  1.00 1.00 Not applicable
   Elective colectomy 3.69 (1.30-10.44) Not applicable 1.00
   Emergent colectomy 5.28 (1.93-14.45) 4.62 (1.66-12.88) 1.59 (0.82-3.07)
VTE prophylaxis2
   No Not applicable 1.00 1.00
   Yes 2.24 (0.99-5.03) 1.38 (0.32-6.00)
In-hospital complication
   No 1.00 1.00 1.00
   Yes 2.68 (1.42-5.05) 2.80 (1.26-6.24) 2.53 (1.32-4.85)
   Year 1.10 (1.01-1.20) Not significant3 Not significant3
1One patient was excluded in each of these cases due to missing data. 2VTE prophylaxis with anticoagulants (e.g., heparin) was assessed preoperatively/in-
hospital for the emergent colectomy and medically responsive cohort, and postoperatively for the emergent and elective colectomy cohort. VTE prophylaxis 
was not modeled for the entire cohort. 3P value was > 0.1 when fitted into the regression model using stepwise selection. The following variables were tested 
in the multivariate model, but were not independent predictors in any of the models: sex, disease duration, comorbidities, extra-intestinal manifestations, 
extent of disease, blood in stool and frequency of bowel movements. 5-ASA: Azathioprine, prednisone, and infliximab; VTE: Venous thromboembolism.
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incidental intra-abdominal VTE was identified in 
the medically responsive group. Thus, some cases 
of VTE that were asymptomatic may have been 
missed. However, the proportion of clinically relevant 
VTE that we missed was likely low. For example, a 
recent study of inpatient and outpatient UC patients 
who were actively flaring, but were asymptomatic 
for a DVT, were not found to have any incidentally 
diagnosed DVT on screening ultrasound[20]. Also, 
we evaluated every case for readmission to hospital 
for a VTE within 6 mo of the discharge from hos-
pital admission. Thus, we were able to capture 
clinically meaningful cases of VTE that were missed 
in hospital or developed post-discharge. Sixteen 
percent of UC patients were readmitted to hospital 
for VTE following discharge from hospital including 
one patient who was readmitted 6 d after discharge 
for mesenteric vein thrombosis that led emergent 
resection of ischemic bowel. Consequently, physicians 
should be aware of this complication, recognize 
the signs and symptoms, and have a low threshold 
to screen for VTE in the extremities and in the 
abdomen in UC patients. 
Current American College of Gastroenterology 
guidelines recommend VTE prophylaxis for all 
patients admitted to hospital with an IBD flare 
as well as all postoperative patients undergoing 
colectomy[23]. The American College of Chest 
Physicians (ACCP) guidelines recommend VTE 
prophylaxis in IBD patients confined to a bed[30]. 
Though, ambulation alone would not prevent intra-
abdominal VTE. In our study, greater than 90% of 
emergent and elective colectomy patients received 
VTE prophylaxis postoperatively. Despite the high 
utilization of postoperative heparin, the occurrence 
of VTE remained high. Similarly, a smaller study 
found that despite adequate postoperative heparin 
use, rates of VTE in post-colectomy patients were 
over 7-fold higher in UC patients as compared to 
patients undergoing surgery for colorectal cancer[31]. 
A randomized controlled trial that included nearly 
600 patients with inflammatory bowel disease 
demonstrated that low dose heparin had significantly 
lower rates of VTE (2.9%) as compared to patients 
randomized to enoxaparin (9.0%)[32]. 
The current ACCP guidelines recommend that 
patients undergoing abdominal or pelvic surgery 
for cancer, with a high risk of postoperative VTE 
(i.e., > 6%) and who do not have increased risk of 
bleeding, should be considered for both mechanical 
and pharmacological VTE prophylaxis and extended 
duration of the latter[30]. Our study was unique from 
prior work because we explored VTE occurrence 
up to 6 mo following discharge from hospital. We 
demonstrated that 16% of our detected VTE were 
diagnosed after discharge from hospital. Our findings 
raise the issue of whether the same consideration for 
extended postoperative VTE prophylaxis should be 
given for IBD surgeries. Prior studies have reported 
lower DVT levels (< 3%) postoperatively for IBD 
surgeries[31,32], as compared to our study. However, 
nearly half of our VTE population experienced an 
intra-abdominal VTE. The clinical significance of 
intra-abdominal VTE is controversial and depends on 
the acuity, size, and location of the thrombosis[33,34]. 
Given the uncertainty, these findings warrant a 
randomized controlled trial to evaluate the efficacy 
of VTE prophylaxis for 4 wk postoperatively.
Only 19% of patients admitted with an UC 
flare who underwent emergent colectomy received 
preoperative VTE prophylaxis. Similarly, only 16% 
of patients who were admitted for an UC flare 
and discharged without colectomy received VTE 
prophylaxis in-hospital. A recent multicenter chart 
audit of 29 Canadian hospitals also demonstrated 
similarly low prophylaxis rates for hospitalized 
medical patients requiring VTE prophylaxis[35]. 
Moreover, patients who received VTE prophylaxis 
were more likely to be diagnosed with a VTE. 
However, this finding likely reflected disease severity 
(i.e., confounding by indication) because a meta-
analysis indicated that heparin is safe to use in an 
acute flare of UC[25,36] and randomized controlled 
trials support the use of VTE prophylaxis in IBD[32]. 
Thus, in the absence of hemodynamically significant 
haemorrhage VTE prophylaxis should be prescribed. 
However, the adequate agent, dose, and duration of 
VTE prophylaxis in medically managed UC patients 
need further evaluation.
Our study could not differentiate whether the 
increased risk of VTE among UC patients undergoing 
colectomy was due specifically to the colectomy 
or was caused by disease severity necessitating 
colectomy. Though, most likely it was due to the 
combination of disease severity and surgery. Thus, 
the optimal approach of preventing VTE is to in-
duce and maintain remission in UC. The majority 
of UC patients were admitted to hospital prior to 
publications demonstrating efficacy of infliximab in 
the hospital[37] and outpatient setting[38]. Additionally, 
recent studies have demonstrated that infliximab 
significantly reduced the risk of colectomy for up 
to 3 years following initiation of treatment[39-41]. 
Because less than 4% of the patients in our study 
were prescribed infliximab, greater utilization of anti-
TNF therapies may lead to reduced colectomy and 
hence, burden of VTE among UC patients. 
Several limitations to this study should be 
considered. While VTE events that resulted in a 
readmission to hospital within 6 mo of hospital 
discharge were captured, UC patients diagnosed 
and managed for VTE as an outpatient following 
discharge from hospital would not have been 
accounted for in this study. Thus, the occurrence of 
VTE may have been underestimated. While chart 
review improves the accuracy of the data and 
minimizes misclassification bias that occur with 
studies using administrative databases[29,42], some 
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data were missed due to incomplete recording in 
the medical chart. For example, we were not able 
to account for the use of oral contraceptive pills 
prior to hospitalization due to unreliable recording 
of this data. This study was not able to confirm if 
other forms of VTE prophylaxis such as graduated 
compression stockings or intermittent pneumatic 
compression devices for hospitalized UC patients 
were utilised. However, these modalities are only 
recommended if heparin is contraindicated because 
they are less effective at preventing proximal 
extremity and intra-abdominal VTE. Also, due to the 
retrospective nature of chart reviews we were not 
able to assess the number of flares from diagnosis 
to admission to hospital or to define disease severity 
using a validated disease activity index (e.g., Mayo 
score). Finally, despite the advantages of designing 
a population-based study, regional practice pattern 
differences may limit generalizability. Consequently, 
we recommend hospitals assess their own utilization 
of heparin prophylaxis and correlate these with VTE 
outcomes. 
VTE occurred commonly in UC patients who 
underwent emergent (8.7%) and elective (4.9%) 
colectomy despite greater than 90% rate of 
postoperative heparin prophylaxis. In contrast, 
about 1% of medically responsive UC inpatients 
experienced a VTE, despite a 16% prophylaxis 
rate. Thus, VTE prophylaxis should be prescribed 
at time of admission in all IBD patients, and 
VTE prophylaxis for flaring UC patients should 
be considered a quality indicator of best clinical 
practice. This population-based study confirmed 
that the necessity of colectomy was significantly 
associated with VTE. The high rates of VTE in 
UC patients who underwent colectomy despite 
postoperative VTE prophylaxis highlights potentially 
serious outcomes associated with surgical mana-
gement of UC. Consequently, these findings em-
phasize the importance of optimizing medical the-
rapy for UC patients. 
ACKNOWLEDGMENTS
We acknowledge the DIMR department for providing 
data from the Calgary Health Zone. Dr. Kaplan is 
supported through a New Investigator Award from 
the Canadian Institute of Health Research and a 
Population Health Investigator Award from the Alberta 
Heritage Foundation for Medical Research. 
COMMENTS
Background
Ulcerative colitis (UC) is a chronic inflammatory condition of the large colon 
that affects young individuals in the prime of their lives. Most patients with UC 
require daily medications to control inflammation. When these medications do 
not work UC patients require an operation (i.e., colectomy) to remove their large 
bowel. 
Research frontiers
Patients with UC are at increased risk of developing a venous thromboembolism 
(VTE), which is a potentially life-threatening complication. Potential risk factors 
for developing VTE among patients with UC include acute flares, hospitalization, 
advanced age, comorbidities, colectomy, and malnutrition. Understanding the 
leading risk factors of VTE for patients with UC will allow physicians to optimize 
prevention of VTE. 
Innovations and breakthroughs
The overall occurrence of VTE among hospitalized patients with UC was nearly 
5%. However, the risk of VTE was low (about 1%) among flaring UC patients 
who were responsive to medical in-hospital management. In contrast, patients 
with UC who underwent an elective colectomy (5%) or emergent colectomy 
(8.7%) had significantly higher occurrence of VTE. In contrast, about 1% of 
medically responsive UC inpatients experienced a VTE.
Applications
Prescription of VTE prophylaxis for UC patients hospitalized for flare was 
suboptimal (< 20%). In contrast, VTE prescriptions postoperatively were high 
(> 90%) following a colectomy for UC. Thus, this data supports both VTE 
prophylaxis and aggressive medical management of ulcerative colitis patients 
to prevent VTE formation.
Terminology
Venous thromboembolism is a blood clot that forms within the venous 
circulation. International Classification of Diseases is a set of codes used by 
hospital health records to document diseases. These coded data can be used 
for research and surveillance purposes. 
Peer review
“This is an excellent original contribution analyzing cohort of 1020 hospitalised 
UC patients towards risk of VTE. The Authors determined that patients who 
underwent elective or emergent colectomy had 4-5-fold increased risk of VTE 
when compared to UC patients treated non-surgically.” 
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